Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2021; 20(04): 414-416
DOI: 10.4103/wjnm.wjnm_147_20
Letter to Editor

Is it necessary to do surgical fixation in metastatic bone disease impending pathologic fracture before 177Lu-prostate-specific membrane antigen radionuclide therapy?

Majid Assadi
Department of Molecular Imaging and Radionuclide Therapy, The Persian Gulf Nuclear Medicine Research Center, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, Iran
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Financial support and sponsorship

Nil.




Publication History

Received: 14 December 2020

Accepted: 26 December 2020

Article published online:
24 March 2022

© 2021. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bögemann M, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging 2020.[in print]
  • 2 Ameb S, Salawu A, Brown JE. Bone health in men with prostate cancer: Review article. Curr Osteoporos Rep 2019;17:527-37.
  • 3 Thang SP, Lam WW, Tong AK, Allen JC Jr., Ler AS, Tay YS, et al. Clinical outcomes of 177lutetium-prostate-specific membrane antigen therapy in advanced prostate cancer-a prospective pilot study in an Asian population. Nucl Med Commun 2020;41:618-28.
  • 4 Mirels HI. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 1989;249:256-64.
  • 5 Damron TA, Morgan H, Prakash D, Grant W, Aronowitz J, Heiner J. Critical evaluation of Mirels' rating system for impending pathologic fractures. Clin Orthop Relat Res 2003;415:S201-7.
  • 6 Challapalli A, Aziz S, Khoo V, Kumar A, Olson R, Ashford RU, et al. Spine and non-spine bone metastases-current controversies and future direction. Clin Oncol (R Coll Radiol) 2020;32:728-44.
  • 7 Snyder BD, Cordio MA, Nazarian A, Kwak SD, Chang DJ, Entezari V, et al. Noninvasive prediction of fracture risk in patients with metastatic cancer to the spine. Clin Cancer Res 2009;15:7676-83.
  • 8 Fisher CG, DiPaola CP, Ryken TC, Bilsky MH, Shaffrey CI, Berven SH, et al. A novel classification system for spinal instability in neoplastic disease: An evidence-based approach and expert consensus from the spine oncology study group. Spine (Phila Pa 1976) 2010;35:E1221-9.